

La Coagulopatia della Cirrosi del Fegato

Armando Tripodi

Angelo Bianchi Bonomi

Hemophilia and Thrombosis Center

IRCCS Cà Granda Maggiore Hospital Foundation

and Humanitas University

Milano, Italy

The Coagulopathy of Cirrhosis: Changing Paradigm

Up to 2004



Cirrhosis as the epitome
of hemorrhagic diseases

Hemostasis in Chronic Liver Disease

The Dogma...

- The concept of a causal relationship between abnormal hemostasis tests and bleeding was widely accepted
- Common practice of screening patients with hemostasis tests
- Treating patients with abnormal values in order to correct the identified abnormalities prior to invasive procedures

The Challenge of the Dogma

Clinical evidence


- Gastrointestinal (GI) bleeding is the most common hemorrhagic event in cirrhosis
- But, conventional coagulation tests do correlate poorly with GI bleeding in cirrhosis
- Coagulation defects do not predict blood product requirement during liver transplantation (*Massicotte, 2008*)

Poor Correlation between Global Conventional Hemostasis Tests and Bleeding

Review of the Literature

- Ewe K. *Dig Dis Sci* 1981; 26; 388
- Segal JB & Dzik WH. *Transfusion* 2005; 45:1413
- Boks AL, et al. *Hepatology* 1986; 6: 79
- Diaz LK & Teruya J. *New Engl J Med* 2001;344:2030
- Grabau CM et al. *Hepatology* 2004;40:484
- Terjung B et al. *Digestion* 2003; 67: 138
- Mc Gill DB et al. *Gastroenterology* 1990; 99: 1396
- Vieira da Rocha E et al. *Clin Gastroenterology and Hepatol* 2009; 7: 988

Liver Bleeding Time
(min)



The Coagulopathy of Cirrhosis: Changing Paradigm

Up to 2004

Cirrhosis as the epitome
of hemorrhagic diseases

2005-2009

The challenge of the
dogma. Rebalanced
hemostasis

(HEPATOLOGY 2005;41:553–558.)

LIVER FAILURE AND LIVER DISEASE
LIVER FAILURE

Evidence of Normal Thrombin Generation in Cirrhosis Despite Abnormal Conventional Coagulation Tests

Armando Tripodi, Francesco Salerno, Veena Chantarangkul, Marigrazia Clerici, Massimo Cazzaniga,
Massimo Primignani, and Pier Mannuccio Mannucci

The role played by coagulation defects in the occurrence of bleeding in cirrhosis is still unclear. This is partly due to the lack of tests that truly reflect the balance of procoagulant and anticoagulant factors *in vivo*. Conventional coagulation tests such as prothrombin time and activated partial thromboplastin time are inadequate to explore the physiological mechanism regulating thrombin, because they do not allow full activation of the main anticoagulant factor, protein C, whose levels are considerably reduced in cirrhosis. We used a thrombin generation test to investigate the coagulation function in patients with cirrhosis.

Thrombin Generation in Platelet-free Plasma

Summary of findings and consequences

- *Findings*

- Plasma coagulation *is not* abnormal in stable cirrhosis when assessed with global tests reflecting the function of both pro- and anti-coagulants

- *Consequences*

- There is little value for the PT & APTT to assess the bleeding risk in cirrhosis
- The common practice of infusing pro-hemostatic agents in cirrhosis should be reconsidered

Additional Evidence Challenging the Dogma

- Fresh frozen plasma when added to cirrhotic plasma does not modify thrombin generation (Tripodi A et al, 2012)
- Fresh frozen plasma transfusion in patients with cirrhosis does not modify thrombin generation (Rassi A, D'Amico E, Tripodi A, et al, 2020)

Rebalanced Primary Hemostasis in Cirrhosis

- Thrombocytopenia is counteracted by increased levels of the adhesive protein VWF (*Lisman T et al 2006*)
- VWF activity is increased by the relatively low levels of ADAMTS-13 (*Feys HB et al 2007*)
- Thrombin generation in platelet-rich plasma is adequate if platelet counts are $>50 \times 10^9/L$ (*Tripodi A, et al, 2006*)

Why do Patients with Cirrhosis Occasionally Bleed?

- The “**restored**” hemostatic balance in cirrhosis may not be as stable as in healthy individuals and, therefore, slight alterations may lead to hemorrhage (or thrombosis)
- Conditions underlying bleeding

Conditions Underlying Bleeding in Cirrhosis

- Portal Hypertension
- Endothelial dysfunction
- Bacterial infections
- Hyperfibrinolysis (?)
- Renal failure

Therapeutic interventions correcting these abnormalities might be more effective than correcting coagulopathy

The Coagulopathy of Cirrhosis: Changing Paradigm



Pathophysiological evidence

- *All Virchow triggers are concomitantly occurring in cirrhosis*
 - Endothelial dysfunction
 - Reduced blood flow
 - Hypercoagulability

CME

Coagulopathy Does Not Fully Protect Hospitalized Cirrhosis Patients from Peripheral Venous Thromboembolism

Patrick G. Northup, M.D., M.H.E.S.,¹ Matthew M. McMahon, M.D.,² A. Parker Ruhl, M.D.,² Scott E. Altschuler, M.D.,¹ Agata Volk-Bednarz, M.D.,³ Stephen H. Caldwell, M.D.,¹ and Carl L. Berg, M.D.¹
¹Division of Gastroenterology and Hepatology, ²School of Medicine, and ³Department of Internal Medicine, University of Virginia Health System, Charlottesville, Virginia

Risk of Venous Thromboembolism in Patients With Liver Disease: A Nationwide Population-Based Case–Control Study

Kirstine Kobberøe Søgaard, MD^{1,2}, Erzsébet Horváth-Puhó, MSc¹, Henning Grønbaek, MD, PhD³, Peter Jepsen, MD¹, Hendrik Vilstrup, MD, PhD, DMSc³ and Henrik Toft Sørensen, MD, PhD, DMSc^{1,2}

Conclusions

- Patients with cirrhosis had a relative VTE risk of 1.7 (CI 1.5-1.9)
- When the analysis was restricted to unprovoked VTE the relative risk was 2.06 (CI 1.8-2.3)

Clinical evidence

- Cirrhotics on LMWH are protected from PVT without bleeding (*Villa, 2012*)
- Patients with high ETP-ratio are at increased risk for de-novo PVT (*La Mura, 2016*)
- High VWF and procoagulant imbalance (high FVIII/PC ratio) predict outcome in cirrhotics (*Kalambokis, 2016*)
- Thrombin may trigger liver fibrosis (*Wanless, 1995*)

Cirrhotics present with

- Low protein C (*anticoagulant driver*)
- High factor VIII (*procoagulant driver*)

BASIC—LIVER, PANCREAS, AND BILIARY TRACT

An Imbalance of Pro- vs Anti-Coagulation Factors in Plasma From Patients With Cirrhosis

ARMANDO TRIPODI,* MASSIMO PRIMIGNANI,‡ VEENA CHANTARANGKUL,* ALESSANDRA DELL'ERA,‡
MARIGRAZIA CLERICI,* ROBERTO DE FRANCHIS,‡ MASSIMO COLOMBO,§ and PIER MANNUCCIO MANNUCCI*

Implications of the Procoagulant Imbalance in Cirrhosis

- Secondary prevention of VTE (VKA or LMWH) should be more extensively used
- Primary PVT prevention should be considered in patients awaiting liver transplant
 - Villa E. et al, 2012
- Other (non coagulation) thrombin effect should be considered in cirrhosis
 - Wanless et al, 1995

Overall Conclusions

- The re-assessment of hemostasis in cirrhosis questions consolidated therapeutic strategies
- **“Correcting”** abnormal hemostasis tests prior to surgery should be reconsidered
- While platelet transfusion may be useful, plasma, anti-fibrinolytics, or pro-coagulants should be used on individual basis
- Cirrhotics are not auto-anticoagulated
- Hyper- rather than hypo-coagulability might be the distinctive feature of cirrhosis